Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Prostate Cancer News

News
Intermittent, Intensified Androgen Deprivation Therapy Provided PSA Survival Benefit for Patients With High-Risk Biochemically Relapsed Prostate Cancer
02/23/2024

Allison Casey 

Allison Casey 
According to interim results from a phase 3 study, the addition of apalutamide to androgen deprivation therapy showed a statistically and clinically significant improvement of PSA progression-free survival among patients with high-risk...
According to interim results from a phase 3 study, the addition of apalutamide to androgen deprivation therapy showed a statistically and clinically significant improvement of PSA progression-free survival among patients with high-risk...
According to interim results...
02/23/2024
Oncology
News
A Look at the Updates in the NCCN Clinical Practice Guidelines For Prostate Cancer
02/09/2024

By Emry Lloyd

By Emry Lloyd
Get a summary of the changes in the NCCN guidelines regarding radiopharmaceuticals, secondary hormone therapy, and treatments for metastatic castration-sensitive prostate cancer.
Get a summary of the changes in the NCCN guidelines regarding radiopharmaceuticals, secondary hormone therapy, and treatments for metastatic castration-sensitive prostate cancer.
Get a summary of the changes in...
02/09/2024
Journal of Clinical Pathways
Conference Coverage
Cabozantinib Plus Atezolizumab Significantly Prolonged PFS in Metastatic Castration-Resistant Prostate Cancer
01/25/2024

Stephanie Holland 

Stephanie Holland 
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3...
01/25/2024
Oncology

Advertisement

News
Real-World Data Shows Benefit of Triplet Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer
01/05/2024
Allison Casey
A real world study found triplet therapy to be an effective and tolerable treatment option for patients with metastatic hormone-sensitive prostate cancer.
A real world study found triplet therapy to be an effective and tolerable treatment option for patients with metastatic hormone-sensitive prostate cancer.
A real world study found triplet...
01/05/2024
Oncology
News
Real-World Outcomes of EBRT Treatment for Patients With Localized Prostate Cancer
03/03/2023

Grace Taylor

Grace Taylor
At the 2023 ASCO GU Cancers Symposium, Lawrence Karsh, MD, and colleagues presented data on real-world outcomes for using external beam radiation therapy to treat patients with high-risk localized prostate cancer (LPC) and...
At the 2023 ASCO GU Cancers Symposium, Lawrence Karsh, MD, and colleagues presented data on real-world outcomes for using external beam radiation therapy to treat patients with high-risk localized prostate cancer (LPC) and...
At the 2023 ASCO GU Cancers...
03/03/2023
Journal of Clinical Pathways
News
Health Care Resource Utilization and Costs Associated With Disease Progression Among Patients With Metastatic Castration-Sensitive Prostate Cancer
06/09/2022

Ellen Kurek

Ellen Kurek
Study results show direct all-cause health care costs in patients with nmCSPC often rose several months prior to diagnosis with metastatic disease.
Study results show direct all-cause health care costs in patients with nmCSPC often rose several months prior to diagnosis with metastatic disease.
Study results show direct...
06/09/2022
Journal of Clinical Pathways

Advertisement

News
In Patients With Unfavorable Intermediate-Risk Prostate Cancer, Brachytherapy Improved Overall Survival Compared with External-Beam Radiotherapy
05/18/2022

Ellen Kurek

Ellen Kurek
Researchers reviewed the National Cancer Database records of nearly 32,000 men diagnosed with UIR prostate cancer to determine if men treated with brachytherapy had rates of survival comparable with those of men treated with EBRT.
Researchers reviewed the National Cancer Database records of nearly 32,000 men diagnosed with UIR prostate cancer to determine if men treated with brachytherapy had rates of survival comparable with those of men treated with EBRT.
Researchers reviewed the...
05/18/2022
Journal of Clinical Pathways
News
Comparing Costs and Health Care Resource Utilization Among Patients With Metastatic, Castration-Resistant vs Nonmetastatic Prostate Cancer
04/19/2022

Ellen Kurek

Ellen Kurek
Findings from a retrospective cohort study suggest that patients with metastatic, castration-resistant prostate cancer experience higher costs, and require more outpatient services, compared with those with nonmetastatic cancer.
Findings from a retrospective cohort study suggest that patients with metastatic, castration-resistant prostate cancer experience higher costs, and require more outpatient services, compared with those with nonmetastatic cancer.
Findings from a retrospective...
04/19/2022
Journal of Clinical Pathways
News
Health Care Costs and Utilization Associated With Open vs Robotic-Assisted Radical Prostatectomy
02/22/2022

Janelle Bradley

Janelle Bradley
Study findings suggest that lower postdischarge health care utilization after robotic-assisted prostatectomy may offset the higher costs during the index hospitalization.
Study findings suggest that lower postdischarge health care utilization after robotic-assisted prostatectomy may offset the higher costs during the index hospitalization.
Study findings suggest that...
02/22/2022
Journal of Clinical Pathways

Advertisement

News
Systematic Review Highlights Complexity of Cost-Effectiveness Models in Prostate Cancer
02/22/2022

Janelle Bradley

Janelle Bradley
This systematic review of cost-effectiveness literature for novel diagnostic methods in prostate cancer shows that most studies have found novel methods to be more cost-effective than standard of care.
This systematic review of cost-effectiveness literature for novel diagnostic methods in prostate cancer shows that most studies have found novel methods to be more cost-effective than standard of care.
This systematic review of...
02/22/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use